



Report #:

COA2607222-002

Page 1 of 2

Title:

## Certificate of Analysis (CoA)



**Date:** 8/7/2026  
**Date Tested:** 8/7/2026  
**Customer:** Hamner Research  
**Testing material:** Semaglutide  
**Lot Number:** 01-2026  
**Content/Potency:** 10 mg  
**Storage:** R.T.  
**Visual Description:** Small clear vial: white sample, holographic label, silver crimp, white plastic cap.  
**Labeled as:** GLP1S  
**Manufacturer:** N/A  
**Testing Purpose:** FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins.



| Test                                         | Method        | Specification                                                                  | Result                                                                                           |
|----------------------------------------------|---------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| General Appearance                           | USP<br><630>  | white powder                                                                   | white powder                                                                                     |
| Mass                                         | USP<br><41>   | As recorded                                                                    | 52.3 mg                                                                                          |
| FTIR Identification and Composition Analysis | USP<br><197A> | Sample spectrum should confirm the content of peptide via characteristic bands | FTIR sample spectrum confirms the presence of Semaglutide with addition of excipient(s)/fillers. |
| HPLC Purity of Peptide Assay                 | USP<br><621>  | Specifications: $\geq 98\%$                                                    | 99.9 %                                                                                           |
| HPLC Potency Assay                           | USP<br><621>  | Specifications: 90 – 110% of 10 mg                                             | 11.1 mg (111.4 %)                                                                                |
| Peptide-to-Excipients Ratio                  | USP<br><1151> | Recommended ratios of (1:2) to (1:10) for (peptide: excipients)                | 11.1 : 41.2 mg (1:3.7)                                                                           |

The results of the CoA relate only to the item(s) tested and applied to the sample as received.

Andrea Castro, BS  
Scientist-II  
BTLabs

Escarlet Cabrieles, BS  
Scientist-II  
BTLabs

5601 Corporate Way | Suite 206 | West Palm Beach, FL 33407

Phone: (561) 625-0133


E-mail: [info@btlabtesting.com](mailto:info@btlabtesting.com) | Website: <https://btlabtesting.com>

Title:

## Certificate of Analysis (CoA)



### FTIR ID and Composition Analysis: Semaglutide Lot 01-2026



### HPLC Purity and Potency Assay @ 280 nm: Semaglutide Lot 01-2026



#### Semaglutide Lot 01-2026 @ 280 nm

| Peak #: | Retention Time (min) | Area (mAU*s) |
|---------|----------------------|--------------|
| 1       | 9.443                | 1841.2       |